Bioventus Inc. (BVS)
NASDAQ: BVS · Real-Time Price · USD
9.01
-0.02 (-0.22%)
Mar 31, 2025, 2:21 PM EDT - Market open
Bioventus Revenue
In the year 2024, Bioventus had annual revenue of $573.28M with 11.89% growth. Bioventus had revenue of $153.64M in the quarter ending December 31, 2024, with 13.45% growth.
Revenue (ttm)
$573.28M
Revenue Growth
+11.89%
P/S Ratio
1.02
Revenue / Employee
$616,430
Employees
930
Market Cap
596.07M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 573.28M | 60.94M | 11.89% |
Dec 31, 2023 | 512.35M | 228.00K | 0.04% |
Dec 31, 2022 | 512.12M | 81.22M | 18.85% |
Dec 31, 2021 | 430.90M | 109.74M | 34.17% |
Dec 31, 2020 | 321.16M | -18.98M | -5.58% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Dec 31, 2013 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BVS News
- 19 days ago - Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million - Benzinga
- 20 days ago - Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025 - GlobeNewsWire
- 3 months ago - Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners - GlobeNewsWire
- 5 months ago - Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Bioventus Reports Third Quarter Financial Results - GlobeNewsWire
- 5 months ago - Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024 - GlobeNewsWire